Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”: [Annals of Oncology 37 (2026) 1220-1229]
Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”: [Annals of Oncology 37 (2026) 1220-1229]. // Annals of Oncology. – URL: https://www.sciencedirect.com/science/article/pii/S0923753426067724?dgcid=rss_sd_all
Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”: [Annals of Oncology 37 (2026) 1220-1229]. Annals of Oncology. https://www.sciencedirect.com/science/article/pii/S0923753426067724?dgcid=rss_sd_all
“Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”: [Annals of Oncology 37 (2026) 1220-1229].” Annals of Oncology.
@article{article36299,
title = {Corrigendum to “Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER)”: [Annals of Oncology 37 (2026) 1220-1229]},
journal = {Annals of Oncology},
url = {https://www.sciencedirect.com/science/article/pii/S0923753426067724?dgcid=rss_sd_all}
}